講師資料
Talks：
Circadian disruptions in neurodegenerative disorders
神經退化性疾病的睡眠節律障礙
Name：
陳彥中（Yen-Chung Chen）
Position：
主治醫師
Affiliation：
中國醫藥大學附設醫院神經部主治醫師
臺中市立老人復健綜合醫院神經內科主治醫師
國立彰化師範大學統計資訊研究所助理教授
國際巴金森暨動作障礙學會實證醫學委員會委員
台灣神經免疫學會副財務長
Email：
Photo：
Research Interests：
Neuroimmunology diseases, Parkinson’s disease, DBS, MRgFUS and echo guided botulinum toxin treatment.
Selected Publications：
1. Chiang, CH., Chen, YC., Nfor, O.N.,Wen-Yu Lu & Yung-Po Liaw*
Interaction between gender and age on the methylation levels of KLF14 promoter. Sci Rep 15, 18283 (2025).
2. Wei-Sheng Wang, Yu-Ping Chiu, Meng-Han Tsai, Shey-Lin Wu, Yen-Chung Chen*
Diagnosing Cerebrotendinous Xanthomatosis in a Middle-Aged Woman with Cervical Dystonia. J Mov Disord. 2025 Jan 20.
3. Teng-Chi Yang, Jen Pi Tsai, Honda Hsu, Yen-Chung Chen, Yi-Chia Liaw, Shu Yi Hsu, Hao Jan Yang, Yung-Po Liaw*
Delving Into the Interaction Between Exercise and Diabetes on Methylation of the FKBP5 Gene. Journal of Diabetes Research Volume 2025
4. Teng-Chi Yang, Yen-Chung Chen, Disline Manli Tantoh, Shu‑Yi Hsu, Honda Hsu, Yi-Chia Liaw, Jen‑Pi Tsai, Hao‑Jan Yang* & Yung-Po Liaw*.
Obstructive sleep apnea and genotype rs6843082 as a risk factor for cerebrovascular accident. Sci Rep 14, 25041 (2024).
5. Chen YC, Liaw YC, Nfor ON, Hsiao CH, Zhong JH, Wu SL*, Liaw YP*.
Epigenetic associations of GPNMB rs199347 variant with alcohol consumption in Parkinson's disease. Front Psychiatry. 2024 Jul 18;15:1377403.
6. Chen JY, Chen YC*, Wu SL*.
Deep Brain Stimulation in Advanced Parkinson's Disease: An Uncommon Case of Allergic Encephalitis. J Mov Disord. 2024 Jul;17(3):345-347.
7. Chen YC, Wang WS, Lewis SJG, Wu SL*.
Fighting Against the Clock: Circadian Disruption and Parkinson’s Disease. J Mov Disord. 2024;17(1):1-14.
Abstract：
Circadian regulation plays a pivotal role in maintaining the integrity of sleep–wake cycles, cognitive functions, and systemic physiology. Increasing evidence indicates that disturbances of circadian rhythms are not merely secondary features of neurodegenerative disorders, but rather integral components of their pathophysiology. In Alzheimer’s disease, Parkinson’s disease, and Huntington’s disease, patients frequently present with early alterations in sleep continuity, rhythm fragmentation, and phase instability. In Parkinson’s disease, REM sleep behavior disorder often emerges years before motor manifestations, suggesting that circadian and sleep disturbances may serve as prodromal markers.
At the molecular level, dysfunction of the core clock machinery—including altered expression of CLOCK, BMAL1, PER, and CRY genes—has been reported in both central pacemakers and peripheral oscillators. Impairments in the suprachiasmatic nucleus, melatonin secretion, and light-input pathways such as intrinsically photosensitive retinal ganglion cells further compromise circadian alignment. These abnormalities are compounded by neuroinflammatory cascades, oxidative stress, and protein misfolding, which appear to interact bidirectionally with circadian dysregulation, accelerating neuronal vulnerability.
From a clinical standpoint, circadian biomarkers including actigraphy-derived rest–activity patterns, body temperature rhythms, hormone secretion profiles, and gene expression signatures provide objective measures that correlate with disease progression and cognitive decline. Recognition of these biomarkers underscores the importance of circadian health as both a clinical outcome and a potential therapeutic target.
Interventions aiming to restore circadian synchrony—ranging from bright light therapy and exogenous melatonin to structured behavioral and pharmacological schedules—demonstrate varying degrees of efficacy. More experimental strategies, such as chronopharmacology and time-restricted feeding, are under investigation in preclinical and early clinical studies.
Taken together, circadian disruption emerges as a unifying theme across neurodegenerative disorders, influencing symptom burden, disease trajectory, and quality of life. Incorporating circadian assessment and chronotherapeutic approaches into clinical practice holds promise for enhancing outcomes and delaying disease progression, yet requires further longitudinal validation and individualized application.
2025年會：